Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT01974258 |
| Title | Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients |
| Recruitment | Withdrawn |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | Yes |
| Sponsors | Hoffmann-La Roche |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
CKB BOOST